Drug Development

driven by
the ambition
to cure

Drug Development Business Model

We bring innovation to patients by bridging the gap

Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop novel therapies to target high unmet medical needs in oncology and infectious diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery programs and international patient reach. We seek out and identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select global partners to maximize worldwide patient access.
Our ultimate purpose is to develop tomorrow’s standard of care to cure cancer and infectious diseases and to improve patient quality of life.

Debiopharm is not a biotech, but a privately owned, unlisted biopharmaceutical company. That means that we have the freedom to explore where science leads us. Our decision to in-license and develop specific drug candidates are always based on scientific rationale and aimed to respond to patient unmet needs.

Debiopharm Business Model presentation

    Do you have a compound?

    We scout for new, innovative pharmaceutical drug candidates to go through our full drug development value chaine, from preclinical to registration.


    Are you interested in one of our programs?

    We are looking for partners for all projects with a focus on our clinically advanced candidates.


Our program pipeline

We currently have a growing pipeline of projects in development in the areas of oncology, infectious disease, and antibody-drug conjugate (ADC) drug technology.

Leadership team

Discover the members who guide and bring long-term vision to drug development

Product portfolio

Discover the treatments we offer via our commercial partners worldwide

Learn more

Discover our latest scientific publications and posters

Read more
Contact us

Would like to partner with us? Got a question or a comment? Get in touch!

Get in touch